Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Axel Vater, PhD +49-30-959 982-140
vater@aptarion.com


Antonio Perez, MD +49-30-959 982-140
perez@aptarion.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Back

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Recruiting

Open to: ALL

Age: 18.0 - 85.0

London Liverpool York Reading Wakefield Bristol Plymouth Cardiff

Medical Conditions

Pneumonia

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this clinical trial is to compare the safety and efficacy of AON-D21 versus placebo, both on top of standard of care, in patients with severe community acquired pneumonia admitted to ICU (or similar unit). The main questions to answer are:

* The safety and tolerability of AON-D21 vs placebo. * The efficacy of AON-D21vs placebo. * The pharmacokinetics of AON-D21. * The pharmacodynamics of AON D21. * To identify biomarkers for patient stratification and analyses in future trials.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Feb 2024 May 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.

Intervention Arm Group : AON-D21 plus Standard of Care;

Intervention Type : DRUG
Intervention Description : Sterile liquid formulation of 5% glucose solution in matched glass vials with a 1.5 mL fill volume.

Intervention Arm Group : Placebo plus Standard of Care;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College London
    London
  • Liverpool University Hospitals NHS Foundation Trust
    Liverpool
  • York Hospital
    York
  • Royal Berkshire Foundation Trust
    Reading
  • Mid Yokshire Teaching NHS Trust
    Wakefield
  • University Hospital Bristol and Weston NHS
    Bristol
  • University Hospitals Plymouth NHS Trust, Derriford Hospital
    Plymouth
  • University Hospital of Wales
    Cardiff

Axel Vater, PhD +49-30-959 982-140
vater@aptarion.com


Antonio Perez, MD +49-30-959 982-140
perez@aptarion.com



The study is sponsored by Aptarion Biotech AG



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05962606
Last updated 01 February 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top